Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Survivin, an inhibitor of apoptosis protein, is overexpressed in most human tumors.
• Survivin's role in cell division and apoptosis inhibition makes it a potential therapeutic target for cancer.
• Targeting survivin offers a novel strategy for developing anticancer therapies.

Purpose of the Study:

• To investigate the therapeutic potential of a hammerhead ribozyme targeting survivin mRNA.
• To assess the effect of survivin expression attenuation on human melanoma cell sensitivity to gamma irradiation.

Main Methods:

• Generated a hammerhead ribozyme targeting the survivin mRNA.
• Stably transfected human melanoma cell lines (JR8 and M14) with the ribozyme vector.
• Selected cell populations with reduced survivin protein levels for further study.
• Assessed cell sensitivity to gamma irradiation using clonogenic survival assays.
• Quantified radiation-induced apoptosis via propidium iodide staining and caspase-3 activity assays.

Main Results:

• Ribozyme-expressing melanoma cells exhibited significantly lower survivin protein levels (-60% and -50%).
• Ribozyme-expressing cells demonstrated significantly increased sensitivity to gamma irradiation (p<0.01).
• Radiation treatment induced markedly greater apoptosis in ribozyme-expressing cells compared to parental cells.

Conclusions:

• Attenuation of survivin expression using a hammerhead ribozyme enhances melanoma cell susceptibility to gamma irradiation.
• This study provides the first evidence that reducing survivin levels sensitizes human melanoma cells to radiation therapy.
• Targeting survivin represents a promising approach for improving the efficacy of anticancer treatments.